2 Low-Cost ETFs With More Than 2,400 Holdings That You Can Buy and Hold for Decades
Investment Strategy: Exchange-traded funds (ETFs) like Schwab U.S. Broad Market ETF and iShares Core S&P Total U.S. Stock Market ETF are recommended for long-term investment due to their low fees, broad market exposure, and diversification, minimizing risk associated with individual stocks.
Performance Overview: Both ETFs have similar performance metrics, with the Schwab fund having a slight tech sector bias and lower overall returns compared to the S&P 500, while the iShares fund offers slightly more diversification and less reliance on tech stocks.
Trade with 70% Backtested Accuracy
Analyst Views on SCHB
About the author
Explore the Details: SCHB Shows Potential for 10% Growth
ETF Analysis: The Schwab US Broad Market ETF (SCHB) has an implied analyst target price of $28.45, indicating a potential upside of 9.87% from its current trading price of $25.89.
Notable Holdings: Key underlying holdings with significant upside potential include Dyne Therapeutics (DYN), Immunovant (IMVT), and Niagen Bioscience (NAGE), with expected price increases of 140.82%, 129.24%, and 105.69% respectively based on analyst targets.
Analysts Predict 10% Growth Potential for SCHB Holdings
ETF Analysis: The Schwab US Broad Market ETF (SCHB) has an implied analyst target price of $28.40 per unit, indicating a potential upside of 10.06% from its recent trading price of $25.80.
Notable Holdings: Key underlying holdings with significant upside potential include Kyverna Therapeutics (KYTX) with a target price of $18.20 (204.86% upside), BICARA Therapeutics (BCAX) with a target of $33.00 (98.68% upside), and Praxis Precision Medicines (PRAX) with a target of $100.00 (88.61% upside).
Dividend Investor Earning $5,200 A Month Shares His Top 7 Stock Picks – 'Getting Dividend is the Biggest Joy in My Life'
Rising Popularity of Dividend Investing: More Americans are turning to dividend investing for secondary income amid market volatility and inflation, with historical data showing dividend stocks in the S&P 500 yielding higher returns than non-dividend stocks.
Successful Dividend Investor Example: A Reddit user shared their portfolio details, revealing a monthly dividend income of $5,240, primarily from various dividend ETFs, highlighting popular funds such as Schwab US Broad Market ETF and Goldman Sachs Nasdaq-100 Premium Income ETF.
ETF Fundamental Report for SCHB
ETF Overview: The Schwab U.S. Broad Market ETF (SCHB) is a Large-Cap Quality ETF with significant exposure to the Technology sector, particularly in Software & Programming.
Investment Research Service: Validea provides investment research based on strategies from renowned investors and offers stock analysis and model portfolios aimed at long-term market outperformance.
Implied SCHB Analyst Target Price: $25
ETF Analyst Target Prices: The Schwab US Broad Market ETF (SCHB) has an implied analyst target price of $25.46, indicating a potential upside of 17.83% from its current trading price of $21.61. Notable underlying holdings with significant upside include Rapport Therapeutics Inc (RAPP), IDEAYA Biosciences Inc (IDYA), and Denali Therapeutics Inc (DNLI).
Investor Research Considerations: Analysts' optimistic target prices may reflect future expectations but could also lead to downgrades if they are based on outdated information. Investors are encouraged to conduct further research to assess the validity of these targets in light of recent developments.
ETF Fundamental Report for SCHB
ETF Overview: The Schwab U.S. Broad Market ETF (SCHB) is a Large-Cap Multi-Factor ETF with significant exposure to the Technology sector, particularly in Software & Programming.
Investment Research: Validea provides analysis on SCHB's investment factors such as value, quality, momentum, and low volatility, along with resources for further research on various ETFs.
Explore the Details: SCHB Shows Potential for 10% Growth
ETF Analysis: The Schwab US Broad Market ETF (SCHB) has an implied analyst target price of $28.45, indicating a potential upside of 9.87% from its current trading price of $25.89.
Notable Holdings: Key underlying holdings with significant upside potential include Dyne Therapeutics (DYN), Immunovant (IMVT), and Niagen Bioscience (NAGE), with expected price increases of 140.82%, 129.24%, and 105.69% respectively based on analyst targets.
Analysts Predict 10% Growth Potential for SCHB Holdings
ETF Analysis: The Schwab US Broad Market ETF (SCHB) has an implied analyst target price of $28.40 per unit, indicating a potential upside of 10.06% from its recent trading price of $25.80.
Notable Holdings: Key underlying holdings with significant upside potential include Kyverna Therapeutics (KYTX) with a target price of $18.20 (204.86% upside), BICARA Therapeutics (BCAX) with a target of $33.00 (98.68% upside), and Praxis Precision Medicines (PRAX) with a target of $100.00 (88.61% upside).
Dividend Investor Earning $5,200 A Month Shares His Top 7 Stock Picks – 'Getting Dividend is the Biggest Joy in My Life'
Rising Popularity of Dividend Investing: More Americans are turning to dividend investing for secondary income amid market volatility and inflation, with historical data showing dividend stocks in the S&P 500 yielding higher returns than non-dividend stocks.
Successful Dividend Investor Example: A Reddit user shared their portfolio details, revealing a monthly dividend income of $5,240, primarily from various dividend ETFs, highlighting popular funds such as Schwab US Broad Market ETF and Goldman Sachs Nasdaq-100 Premium Income ETF.
ETF Fundamental Report for SCHB
ETF Overview: The Schwab U.S. Broad Market ETF (SCHB) is a Large-Cap Quality ETF with significant exposure to the Technology sector, particularly in Software & Programming.
Investment Research Service: Validea provides investment research based on strategies from renowned investors and offers stock analysis and model portfolios aimed at long-term market outperformance.
Implied SCHB Analyst Target Price: $25
ETF Analyst Target Prices: The Schwab US Broad Market ETF (SCHB) has an implied analyst target price of $25.46, indicating a potential upside of 17.83% from its current trading price of $21.61. Notable underlying holdings with significant upside include Rapport Therapeutics Inc (RAPP), IDEAYA Biosciences Inc (IDYA), and Denali Therapeutics Inc (DNLI).
Investor Research Considerations: Analysts' optimistic target prices may reflect future expectations but could also lead to downgrades if they are based on outdated information. Investors are encouraged to conduct further research to assess the validity of these targets in light of recent developments.
ETF Fundamental Report for SCHB
ETF Overview: The Schwab U.S. Broad Market ETF (SCHB) is a Large-Cap Multi-Factor ETF with significant exposure to the Technology sector, particularly in Software & Programming.
Investment Research: Validea provides analysis on SCHB's investment factors such as value, quality, momentum, and low volatility, along with resources for further research on various ETFs.
